GCG and Parkinson disease: Indeed, a recent phase II clinical trial of glucagon-like peptide-1 (GLP-1)/incretin for PD appeared promising (Hölscher, 2012; Athauda et al., 2017), prompting initiation of a subsequent clinical trial of GLP-1/incretin in AD (Gejl et al., 2016).